文献速递神经免疫认知障碍与痴呆

快速髓鞘磁共振成像在多发性硬化中的验证

Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis.
PubMed 文献 · Ann Neurol · 2020-03-02

本研究评估了基于同步T1/T2弛豫测量与质子密度成像的快速髓鞘成像技术在多发性硬化中的特异性、稳健性及临床价值。离体3个脑样本和71例患者与21名健康对照的前瞻性队列显示,髓鞘分数与组织学染色相关,患者全脑及表现正常白质髓鞘分数降低并与基线和随访残疾相关,该技术快速且已获临床批准,有望作为监测髓鞘动态的生物标志物。

要点

  • 快速髓鞘成像与髓鞘相关染色相关,精度良好。
  • 多发性硬化患者全脑及表现正常白质髓鞘分数低于对照。
  • 髓鞘分数与基线及2年随访身体残疾相关。

核心结论

  • 快速髓鞘成像可稳健量化多发性硬化表现正常组织中的弥漫性脱髓鞘,并与认知和临床残疾相关。

研究设计与样本

  • 离体3个多发性硬化脑样本及前瞻性队列71例多发性硬化患者和21名年龄性别匹配健康对照,子队列重复扫描。

主要发现

  • 快速髓鞘成像与蛋白脂蛋白免疫染色和Luxol fast blue染色相关,精度良好。
  • 患者全脑和表现正常白质标准化髓鞘分数低于对照,与基线认知和身体残疾相关。
  • 纵向髓鞘分数与随访身体残疾相关,校正基线残疾后仍相关。

临床怎么用

  • 该技术快速、自动后处理且获美国食品药品监督管理局/CE临床批准,可作为监测髓鞘动态和评估促髓鞘再生治疗的可行生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Magnetic resonance imaging (MRI) is essential for multiple sclerosis diagnostics but is conventionally not specific to demyelination. Myelin imaging is often hampered by long scanning times, complex postprocessing, or lack of clinical approval. This study aimed to assess the specificity, robustness, and clinical value of Rapid Estimation of Myelin for Diagnostic Imaging, a new myelin imaging technique based on time-efficient simultaneous T1 /T2 relaxometry and proton density mapping in multiple sclerosis. METHODS: Rapid myelin imaging was applied using 3T MRI ex vivo in 3 multiple sclerosis brain samples and in vivo in a prospective cohort of 71 multiple sclerosis patients and 21 age/sex-matched healthy controls, with scan-rescan repeatability in a subcohort. Disability in patients was assessed by the Expanded Disability Status Scale and the Symbol Digit Modalities Test at baseline and 2-year follow-up. RESULTS: Rapid myelin imaging correlated with myelin-related stains (proteolipid protein immunostaining and Luxol fast blue) and demonstrated good precision. Multiple sclerosis patients had, relative to controls, lower normalized whole-brain and normal-appearing white matter myelin fractions, which correlated with baseline cognitive and physical disability. Longitudinally, these myelin fractions correlated with follow-up physical disability, even with correction for baseline disability. INTERPRETATION: Rapid Estimation of Myelin for Diagnostic Imaging provides robust myelin quantification that detects diffuse demyelination in normal-appearing tissue in multiple sclerosis, which is associated with both cognitive and clinical disability. Because the technique is fast, with automatic postprocessing and US Food and Drug Administration/CE clinical approval, it can be a clinically feasible biomarker that may be suitable to monitor myelin dynamics and evaluate treatments aiming at remyelination. ANN NEUROL 2020;87:710-724.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Ouellette R, Mangeat G, Polyak I, et al. Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis. Ann Neurol. 2020. PMID: 32057118. doi:10.1002/ana.25705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。